Patents by Inventor Bert Schepens
Bert Schepens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101647Abstract: Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.Type: ApplicationFiled: February 7, 2022Publication date: March 28, 2024Inventors: Xavier SAELENS, Dorien DE VLIEGER, Iebe ROSSEY, Sieglinde DE CAE, Koen SEDEYN, Loes VAN SCHIE, Hannah EECKHAUT, Daria FIJALKOWSKA, Catelijne STORTELERS, Bert SCHEPENS, Nico CALLEWAERT, Han REMAUT, Wim NERINCKX, Kenny ROOSE, Dirk REITER
-
Publication number: 20230227537Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.Type: ApplicationFiled: February 5, 2021Publication date: July 20, 2023Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
-
Patent number: 11248039Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: September 10, 2019Date of Patent: February 15, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Patent number: 11040963Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.Type: GrantFiled: February 1, 2018Date of Patent: June 22, 2021Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Maria Van Dongen, Jaroslaw Juraszek, Griet Wim Bert Schepens, Charles Edward Lawson, Brian Shook, Maria Tim Hugo Jonckers, Abdellah Tahri, Bernard Pierre Jean-Marie Raboisson, Nestor CHristophe Francis Robert Buyck
-
Publication number: 20210106673Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: October 23, 2020Publication date: April 15, 2021Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Publication number: 20200102374Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: ApplicationFiled: September 10, 2019Publication date: April 2, 2020Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
-
Publication number: 20200010459Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.Type: ApplicationFiled: February 1, 2018Publication date: January 9, 2020Inventors: Maria VAN DONGEN, Jaroslaw JURASZEK, Griet Wim Bert SCHEPENS, Charles Edward LAWSON, Brian SHOOK, Maria Tim, Hugo JONCKERS, Abdellah TAHRI, Bernard Pierre, Jean-Marie RABOISSON, Nestor CHristophe, Francis, Robert BUYCK
-
Patent number: 10501528Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: June 20, 2016Date of Patent: December 10, 2019Assignees: V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Publication number: 20190083605Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: September 27, 2018Publication date: March 21, 2019Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 10117926Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: GrantFiled: June 29, 2016Date of Patent: November 6, 2018Assignees: VIB VZW, UNIVERSITEIT GENTInventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Publication number: 20180179266Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: ApplicationFiled: June 20, 2016Publication date: June 28, 2018Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
-
Patent number: 9725522Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: March 8, 2016Date of Patent: August 8, 2017Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Publication number: 20160346379Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: June 29, 2016Publication date: December 1, 2016Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Publication number: 20160280799Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: ApplicationFiled: March 8, 2016Publication date: September 29, 2016Applicant: Ablynx NV.Inventors: MARIE-PAULE LUCIENNE ARMANDA BOUCHE, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Patent number: 9409973Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: GrantFiled: November 15, 2011Date of Patent: August 9, 2016Assignees: VIB VZW, Universiteit GentInventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 9320792Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: February 7, 2013Date of Patent: April 26, 2016Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Patent number: 9193780Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: June 5, 2009Date of Patent: November 24, 2015Assignee: Ablynx N.V.Inventors: Anna Hultberg, Bram Maassen, Peter Vanlandschoot, Erik Depla, Catelijne Stortelers, Cornelis Theodorus Verrips, Steven Van Gucht, Jose Melero, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Robert Anthony Weiss, Nigel J. Temperton, Xavier Saelens, Bert Schepens, Alexander Szyroki, Michael Marie Harmsen
-
Publication number: 20130315916Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: November 15, 2011Publication date: November 28, 2013Applicants: Universiteit Gent, VIB VZWInventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Publication number: 20110311515Abstract: The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: ApplicationFiled: January 14, 2010Publication date: December 22, 2011Applicant: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens
-
Publication number: 20110182897Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: June 5, 2009Publication date: July 28, 2011Inventors: Anna Hultberg, Bram Maassen, Peter Vanlandschoot, Erik Depla, Catelijne Stortelers, Cornelis Theodorus Verrips, Steven Van Gucht, Jose Melero, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Robert Anthony Weiss, Nigel J. Temperton, Xavier Saelens, Bert Schepens, Alexander Szyroki, Michael Marie Harmsen